

75mg
150mg
300mg
600mg
Mean (SD) Serum Concentration (mg/L)
100
80
60
40
20
0
0 1 3 7 10 14 17 21 24 28 35 42 49 56
Nominal Time (Day)

Figure 1



Baseline
T0
15 sec
30 sec
Needle Out +1 min
GA+CA
Fast Injection
Slow Injection
2 min
4 min
6 & 8 min
10 min
Needle Out +1 min
GA+CA
PP=Present pain/discomfort; PI=Pain/discomfort on needle insertion; PR=Pain/discomfort on needle removal;
GA=Global Assessment; CA=Comparative Assessment
= Needle in
= Needle out
= Injection start
= Injection stop

Figure 2



Percent of Responders
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
0
10
20
30
40
50
1
4
8
15
22
25
29
36
43
50
57
64
71
85

Figure 3



Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses
IGA Score Change from Baseline (SE)
Nominal Study Day
1
4
8
15
22
25
29
36
43
50
57
64
71
85

Figure 4



IGA Score % Change from BL (SE)
10
0
-10
-20
-30
-40
-50
Placebo
mAbl 75 mg SC
mAbl 150 mg SC
mAbl 300 mg SC
All mAbl Doses
1
4
8
15
22
25
29
36
43
50
57
64
71
85
Nominal Study Day

Figure 5



EASI Score Change from Baseline (SE)
10
0
-10
-20
-30
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 6



EASI Score % Change from Baseline (SE)
20
0
-20
-40
-60
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 7



Percent of Responders
100
90
80
70
60
50
40
30
20
10
0
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 8



BSA Change from Baseline (SE)
20
10
0
-10
-20
-30
-40
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 9



BSA Percent Change from Baseline (SE)
40
20
0
-20
-40
-60
-80
1
15
29
36
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 10



5-D Pruritus Score Chg from BL (SE)
5
0
-5
-10
-15
1
15
29
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 11



5-D Pruritus Score % Chg from BL (SE)
20
0
-20
-40
-60
1
15
29
43
57
71
85
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 12



Avg Weekly NRS Chg from BL (SE)
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 13



Avg Weekly NRS % Chg from BL (SE)
Nominal Study Day
Placebo
mAb1 75 mg SC
mAb1 150 mg SC
mAb1 300 mg SC
All mAb1 Doses

Figure 14



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in BSA
0
-5
-10
-15
-20
-25
-30
-35
-40
-45
0
1
2
3
4
5
Study Week

Figure 15



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in IGA Score
0
-5
-10
-15
-20
-25
-30
-35
-40
0
1
2
3
4
5
Study Week

Figure 16



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Percent Change in EASI Score
20
10
0
-10
-20
-30
-40
-50
-60
-70
0
1
2
3
4
5
Study Week

Figure 17



Placebo (N=16)
75 mg (n=8)
150 mg (n=22)
300 mg
Percent Change in Average Weekly NRS Score
0
-5
-10
-15
-20
-25
-30
-35
-40
-45
-50
0
1
2
3
4
5
Study Week

Figure 18



Placebo, EASI-25
300 mg, EASI-25
Placebo, EASI-50
300 mg, EASI-50
Placebo, EASI-75
300 mg, EASI-75
% Patients
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
Study Week

Figure 19



300 mg (n=21)
150 mg (n=22)
75 mg (n=8)
Placebo (n=16)
Day 1
Day 15
Day 29
Day 36
Day 43
Day 57
Day 71
Day 85
0
10
20
30
40
50
60
70
80
90
100

Figure 20



EASI-25
EASI-50
EASI-75
% Patients
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Placebo
75 mg
150 mg
300 mg
All Doses Combined
Treatment Group

Figure 21



Placebo (n=16)
75 mg (n=8)
150 mg (n=22)
300 mg (n=21)
Proportion achieving IGA score of 0 or 1
0
2
4
6
8
10
12
14
16
18
20
0
0.5
1
2
3
3.5
4
Study Week

Figure 22



EASI Score % Change from Baseline (SE)
25
0
-25
-50
-75
-100
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day
Placebo
mAb1 100 mg SC

Figure 23



Percent of Responders
Nominal Study Day
Placebo
0
10
20
30
40
50
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 24



Percent of Responders
Nominal Study Day
Placebo
1 8 15 22 29 36 43 50 57 64 71 78 85
0 10 20 30 40 50 60 70 80 90 100

Figure 25



Percent of Responders
Nominal Study Day
Placebo
mAb1 300 mg SC
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 26



Placebo
mAb1 300 mg SC
EASI Score Change from Baseline (SE)
10
0
-10
-20
-30
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 27



IGA Score Change from Baseline (SE)
Nominal Study Day
Placebo
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 28



IGA Score Percent Change from Baseline (SE)
25
0
-25
-50
-75
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day
Placebo
mAb1 300 mg SC

Figure 29



Placebo
mAb1 300 mg SC
BSA Change from Baseline (SE)
10
0
-10
-20
-30
-40
1
8
15
22
29
36
43
50
57
64
71
78
85
Nominal Study Day

Figure 30



SCORAD Change from Baseline (SE)
Nominal Study Day
Placebo
mAb1 300 mg SC
25
0
-25
-50
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 31



Placebo
tocAb1 300 mg SC
Average Weekly NRS Chg from Baseline (SE)
Nominal Study Day
1
8
15
22
29
36
43
50
57
64
71
78
85

Figure 32



5-D Pruritus Score Change from Baseline (SE)
Nominal Study Day
Placebo
mAb1 300 mg SC
1
15
29
43
57
71
85

Figure 33



EASI Score Pct Chg (SE)
Nominal Study Day
Placebo
mAb1 300 mg SC
0
-10
-20
-30
-40
-50
-60
-70
-80
-90
-100
1
8
15
22
29
36
50
64
78

Figure 34



EASI Score Chg (SE)
0
-10
-20
-30
1
8
15
22
29
36
50
64
78
Nominal Study Day

Figure 35



Percent of Responders
100
90
80
70
60
50
40
30
20
10
0
1
8
15
22
29
36
50
64
78
Nominal Study Day
Placebo
300 mg SC

Figure 36



Probability of Response
Placebo
mAb1 300 mg s.c.
Log-Rank p-value 0.0071
100
90
80
70
60
50
40
30
20
10
0
1
8
15
22
29
36
43
50
56
63
70
77

Figure 37



IGA Score Pct Chg (SE)
0
-10
-20
-30
-40
-50
-60
-70
1
8
15
22
29
36
50
64
78
Nominal Study Day
Placebo
EBB mAb1 300 mg SC

Figure 38



IGA Score Chg (SE)
0
-1
-2
-3
1
8
15
22
29
36
50
64
78
Nominal Study Day
Placebo
mAb1 300 mg SC

Figure 39



Placebo
BBD mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 40



Probability of Response
Nominal Study Day
Placebo
mAb1 300 mg SC
Log-Rank p-value 0.3384

Figure 41



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
1
8
15
22
29
36
50
64
78
10
20
30
40
50
60
70
80
90
100

Figure 42



Placebo
mAb1 300 mg SC
Percent of Responders
Nominal Study Day
0
10
20
30
40
50
60
70
80
90
100
1
8
15
22
29
36
50
64
78

Figure 43



SCORAD Pct Chg (SE)
Nominal Study Day
Placebo
mAb1 300 mg SC
0
-10
-20
-30
-40
-50
-60
-70
-80
1
8
15
22
29
36
50
64
78

Figure 44



SCORAD Chg (SE)
0
-10
-20
-30
-40
-50
1
8
15
22
29
36
50
64
78
Nominal Study Day
Placebo
300 mg SC

Figure 45



Placebo
mAb1 300 mg SC
Pruritus NRS Score Pct Chg (SE)
Nominal Study Day
1
8
15
22
29
36
50
64
78
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80

Figure 46



Placebo
mAb1 300 mg SC
Pruritus NRS Score Chg (SE)
Nominal Study Day
1
8
15
22
29
36
50
64
78
1
0
-1
-2
-3
-4
-5
-6

Figure 47



Mean (+/- SEM)
Median
Baseline IgE (kU/L)
700
600
500
400
300
200
100
0
Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
6 mg/kg
12 mg/kg
Study Treatment

Figure 48A



Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg
Median % Change IgE from Baseline
Study Day
20
10
0
-10
-20
-30
-40
0
10
20
30
40
50
60
70
80
90

Figure 48B



Mean (+/-SEM)
Median
Serum TARC (pg/mL)
1000
900
800
700
600
500
400
300
200
100
0
Placebo
1 mg/kg
150 mg
3 mg/kg
300 mg
8 mg/kg
12 mg/kg
Study Treatment

Figure 49A



Mean % Change TARC
Study Day
Mean % Change TARC from Baseline
40
30
20
10
0
-10
-20
-30
1
85
155
225
365
435
505
575
645
715
785
855

Figure 49B



Mean % Change TARC from Baseline
40
30
20
10
0
-10
-20
1
8
15
22
29
36
43
50
57
64
71
78
85
Study Day
All mAb1
All Placebo

Figure 50



Distribution of Baseline TARC Levels
Placebo
150 mg mAb1
300 mg mAb1
All Patients
# of Patients in Treatment Group
Baseline TARC Range (pg/mL)

Figure 51A



Distribution of Baseline Total Serum IgE Levels
Placebo
150 mg mAb1
300 mg mAb1
All patients
Patients in Treatment Group
0
1
2
3
4
5
6
7
8
<150
150-499
500-999
1000-1999
2000-2999
3000-3999
4000-4999
5000-6999
7000-8999
9000-10999
11000-12999
13000-14999
15000-19999
20000-30000
>30000
Baseline IgE Range (kU/L)

Figure 51B




Placebo
150 mg mAb1
300 mg mAb1
All Patients
Patients Per Group
0
2
4
6
8
10
12
14
16
18
20
0-199
200-299
300-399
400-499
Baseline LDH Range (U/L)

Figure 51C



Study Day	-15	1	3	5	8	12	15	19	22	26	29	33	36	40	43	47	50	54	57	61	64	68	71	75	78	82	85
Placebo n	10	10	9	8	6	6	6	6	5	5	5	4	4	4	4	4	4	4	4	4	4	4	3	3	3	3	3
150 mg n	14	13	13	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	11	11	11	11	10
300 mg n	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	13	11	11	11	11	10

Figure 52





End Of Study
2° endpoint
Last dose
Median % Change LDH from Baseline
Study Day
150 mg mAb1
300 mg mAb1
Placebo
Study Day
Placebo
150mg
300mg

Figure 53




Study Day	1	3	5	8	15	22	29	36	43	50	57	64	71	78	85
Placebo n	9	10	9	8	6	6	6	5	4	4	4	4	4	4	4
150 mg n	13	13	12	11	11	11	11	11	11	11	10	9	10	10	9
300 mg n	13	13	13	13	13	13	13	11	9	10	11	11	11	11	10

Figure 54



Day	1	8	15	22	29	36	43	50	57	64	71	85	113	141	169	197
PBO	53	53	51	46	43	35	31	31	28	29	24	43	8	9	9	25
mAb1	53	52	50	50	47	46	46	47	49	46	47	54	22	24	21	42

Figure 55



Day	1	8	15	22	29	36	43	50	57	64	71	85	113	141	155	169	183	197
PBO	52	53	49	46	43	34	31	31	29	29	23	42	8	9	7	9	6	25
mAb1	53	52	50	49	47	45	46	47	49	45	46	53	22	24	20	21	19	44

Figure 56